DATA SUPPLEMENT

Safety and Efficacy of Combination Nivolumab Plus Ipilimumab in Patients with Advanced Melanoma: Results from a North American Expanded Access Program (CheckMate 218)

F. Stephen Hodi, Paul B. Chapman, Mario Sznol, Christopher D. Lao, Rene Gonzalez, Michael Smylie, Gregory A. Daniels, John A. Thompson, Ragini Kudchadkar, William Sharfman, Michael Atkins, David R. Spigel, Anna Pavlick, Jose Monzon, Kevin B. Kim, Scott Ernst, Nikhil I. Khushalani, Wim van Dijck, Maurice Lobo, David Hogg

Supplementary Tables

Table S1: Summary of adverse events reported between first dose and 30 days after last dose of the EAP therapy that required immune modulating medications in ≥1% of patients

	Nivolumab plus ipilimumab (*N*=754)	
	Any grade, *N* (%)[a]	**Grade 3–4, *N* (%)**
Any adverse event	600 (80)	332 (44)
Diarrhea	132 (18)	52 (7)
Maculopapular rash	115 (15)	22 (3)
Colitis	76 (10)	57 (8)
Increased alanine aminotransferase	72 (10)	47 (6)
Increased aspartate aminotransferase	58 (8)	32 (4)
Rash	52 (7)	3 (<1)
Pruritus	47 (6)	3 (<1)
Pneumonitis	39 (5)	9 (1)
Hypophysitis	38 (5)	5 (1)
Autoimmune hepatitis	37 (5)	28 (4)
Pruritic rash	29 (4)	0
Generalized pruritus	22 (3)	3 (<1)
Nausea	20 (3)	5 (1)
Adrenal insufficiency	18 (2)	3 (<1)
Generalized rash	15 (2)	5 (1)
Fatigue	14 (2)	3 (<1)
Malignant neoplasm progression	12 (2)	11 (1)
Arthralgia	12 (2)	2 (<1)
Vomiting	12 (2)	2 (<1)
Uveitis	11 (1)	1 (<1)
Headache	11 (1)	1 (<1)
increased transaminases	11 (1)	8 (1)
Macular rash	11 (1)	2 (<1)
Pyrexia	10 (1)	1 (<1)
Increased lipase	10 (1)	9 (1)
Acute kidney injury	9 (1)	6 (1)
Hepatitis	9 (1)	6 (1)
Cough	9 (1)	0
Acneiform dermatitis	9 (1)	0
Abdominal pain	8 (1)	2 (<1)

[a]One grade 5 adverse event (due to malignant neoplasm progression) was reported.

Table S2: Immune-modulating concomitant medication for adverse event management

	Nivolumab plus ipilimumab (*N*=754)
Corticosteroid for systemic use	571 (76)
Prednisone	463 (61)
Methylprednisolone	235 (31)
Hydrocortisone	105 (14)
Dexamethasone	88 (12)
Triamcinolone	52 (7)
Meprednisone	32 (4)
Budesonide	17 (2)
Betamethasone	13 (2)
Cortisone	7 (1)
Fludrocortisone	6 (1)
Prednisolone	6 (1)
Steroid	3 (<1)
Corticosteroid	1 (<1)
Corticosteroid, dermatological prep	208 (28)
Topical hydrocortisone	74 (10)
Topical triamcinolone	56 (7)
Clobetasol	40 (5)
Topical prednisolone	15 (2)
Topical betamethasone	14 (2)
Topical cortisone	9 (1)
Topical fluticasone	6 (1)
Fluocinonide	5 (1)
Mometasone	5 (1)
Topical dexamethasone	3 (<1)
Topical prednisone	3 (<1)
Betatp/Saltop	2 (<1)
Halobetasol	2 (<1)
Topical steroid	2 (<1)
Topical corticosteroid	1 (<1)
Desoximetasone	1 (<1)
Difluprednate	1 (<1)
Fluocinolone	1 (<1)
Immunosuppressive agent	92 (12)
Infliximab	67 (9)
Mycophenolic acid	24 (3)
Azathioprine	2 (<1)
Adalimumab	1 (<1)
Tacrolimus	1 (<1)
Anti-asthmatic	13 (2)

	Nivolumab plus ipilimumab (*N*=754)
Fluticasone	5 (1)
Budesi/Formo	4 (1)
Beclomethasone	2 (<1)
Beclomethasone inhaler	2 (<1)
Fluticasone inhaler	1 (<1)
Immune sera and immunoglobulin	5 (1)
Gamma globulin	5 (1)
Immunomodulating agent	4 (1)
Filgrastim	4 (1)
Ophthalmological	4 (1)
Dexa/tobra	2 (<1)
Loteprednol	2 (<1)
Vasoprotective	3 (<1)
Hctop/Pramox	2 (<1)
Cincho/escul/framyc/hctop	1 (<1)

Supplementary Figures



Fig. S1 CheckMate 218 EAP design. [a]Patients may have been treated beyond progression under protocol-defined circumstances. [b]Patients who discontinued the EAP treatment may have been followed for adverse events. CTLA-4, cytotoxic T lymphocyte antigen-4; PD-1, programmed death 1.